Sensorion SAS ALSEN

MONTPELLIER, France & CAMBRIDGE, Mass., September 23, 2026--Regulatory News: Sensorion (FR001401A9Z0 – ALSEN) ("the Company") a pioneering clinical-stage biotechnology company focused on developing novel therapies to restore hearing and treat and prevent hearing loss disorders, today reported its half-year 2026 results, provided a corporate update and announced the availability of its half-year report.

MONTPELLIER, France & CAMBRIDGE, Mass., September 18, 2026--Regulatory News: Sensorion (FR001401A9Z0 – ALSEN) ("the Company"), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces registration and connection details for its SENS-601 Program Day, to be held on September 22, 2026.

Sensorion (ENXTPA:ALSEN) has completed a reverse share split, exchanging every 50 existing shares for 1 new share. The consolidated stock is now trading in Paris under a new ISIN. Recent trading shows Sensorion under pressure, with the share price at €9.70 after declines of about 7% over one day, 19% over the past week and 34% across the last month. This continues a longer pattern of weak total shareholder returns over one, three and five years. This softer momentum sits alongside the new...

MONTPELLIER, France & CAMBRIDGE, Mass., September 16, 2026--Regulatory News: Sensorion (FR001401A9Z0 – ALSEN) ("the Company") a pioneering clinical-stage biotechnology company focused on developing novel therapies to restore hearing and treat and prevent hearing loss disorders, announced today that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (the "SEC").

MONTPELLIER, France & CAMBRIDGE, Mass., September 15, 2026--Regulatory News: Sensorion (FR001401A9Z0 – ALSEN) ("the Company"), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces the completion of the reverse share split of the shares composing the Company's share capital, as decided by the Chief Executive Officer on July 27th, 2026, following sub-delegation granted by the Board

MONTPELLIER, France & CAMBRIDGE, Mass., September 03, 2026--Regulatory News: Sensorion (FR0012596468 – ALSEN) ("the Company") a pioneering clinical-stage biotechnology company focused on developing novel therapies to restore hearing and treat and prevent hearing loss disorders, today announced that it has received authorization from the ANSM to initiate HearConnex, a Phase I/II clinical trial of SENS-601, the Company’s lead gene therapy candidate for GJB2-related hearing loss, in France. Pathoge

MONTPELLIER, France & CAMBRIDGE, Mass., July 29, 2026--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces the implementation of the reverse share split of its shares.

A strategic review determined that the development environment had "notably changed," leading Sensorion to end work on its gene therapy for OTOF-related hearing loss.

MONTPELLIER, France & CAMBRIDGE, Mass., June 10, 2026--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the selection of SENS-601 which addresses GJB2-related hearing loss as its lead program. A Clinical trial application has been filed in Canada and France to evaluate the safety, tolerability and efficacy of intra-cochlear ad